Metropolitan Life Insurance Co. NY reduced its position in shares of Agilent Technologies Inc (NYSE:A) by 10.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,564 shares of the medical research company’s stock after selling 5,398 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in Agilent Technologies were worth $2,941,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Bray Capital Advisors raised its position in shares of Agilent Technologies by 12,000.0% in the second quarter. Bray Capital Advisors now owns 3,025 shares of the medical research company’s stock valued at $187,000 after purchasing an additional 3,000 shares during the period. Point72 Asia Hong Kong Ltd raised its position in shares of Agilent Technologies by 303.2% in the first quarter. Point72 Asia Hong Kong Ltd now owns 2,859 shares of the medical research company’s stock valued at $191,000 after purchasing an additional 2,150 shares during the period. Pwmco LLC bought a new position in shares of Agilent Technologies in the second quarter valued at about $226,000. First Allied Advisory Services Inc. bought a new position in shares of Agilent Technologies in the second quarter valued at about $235,000. Finally, Delpha Capital Management LLC bought a new position in shares of Agilent Technologies in the first quarter valued at about $254,000.
Several equities analysts have recently weighed in on A shares. Morgan Stanley increased their price objective on shares of Agilent Technologies from $83.00 to $84.00 and gave the company an “overweight” rating in a research report on Wednesday, August 15th. ValuEngine raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Wednesday, July 25th. Deutsche Bank increased their price objective on shares of Agilent Technologies from $77.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, August 15th. Zacks Investment Research raised shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $74.00 price objective on the stock in a research report on Tuesday, August 7th. Finally, Goldman Sachs Group raised shares of Agilent Technologies from a “buy” rating to a “conviction-buy” rating in a research report on Monday. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $75.67.
A stock opened at $68.85 on Monday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.00 and a current ratio of 3.62. Agilent Technologies Inc has a 52 week low of $60.42 and a 52 week high of $75.00. The stock has a market capitalization of $21.65 billion, a P/E ratio of 29.17, a price-to-earnings-growth ratio of 2.33 and a beta of 1.35.
Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Tuesday, August 14th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.63 by $0.04. The firm had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.20 billion. Agilent Technologies had a net margin of 6.20% and a return on equity of 18.61%. The business’s revenue for the quarter was up 8.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.59 earnings per share. analysts predict that Agilent Technologies Inc will post 2.71 EPS for the current year.
In other Agilent Technologies news, Director Paul N. Clark sold 2,876 shares of the stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $68.60, for a total transaction of $197,293.60. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Heidi Fields sold 5,482 shares of the stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $67.73, for a total transaction of $371,295.86. The disclosure for this sale can be found here.
Agilent Technologies Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.
Read More: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.